Pharmacovigilance – Products

Deep Breath Intelligence is pleased to announce the launch of a simple breath test that can provide reliable estimates of circulating concentrations of the antiseizure medication valproic acid to aid patient management.

VectorBuilder Inc. has announced its plan to invest $30 million to build an "AAV Superbank" for the research and drug discovery community.

Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from the dosing of the second cohort.

Precision BioSciences, Inc., has announced its latest program updates across its allogeneic CAR T pipeline.

Waters Corporation has unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry 2022 Annual Conference.

Agilent Technologies Inc. has announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools.

Charged Aerosol detection (CAD) can be used to complement your HPLC-UV analysis in a situation where excipients in a formula are a mix of UV active and inactive components. Using these tools together gives you a robust and reliable analytical detection method to determine the stability of all vaccine excipients.

Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy, and combination immunotherapies increase cost of treatment and heighten the risk for toxicity-related adverse events.

Discover more with the first and only technology that can measure 7,000 proteins over a broad range of concentrations. Built on 20 years of pioneering proteomics technology, The SomaScan Assay enables unprecedented biomarker and drug discovery and now, you can seamlessly transition from discovery to validation with new SomaScan panels and SomaSignal TM Tests bolstering the entire drug discovery and development pipeline, all via a straightforward fee-for-service model.

Researchers from the University of Dundee and Promega Corporation have shown how a “three-headed hydra” significantly improves efficacy in targeted protein degradation.